Key Presentations at ASCO 2021 Review Primary Prevention of Prostate Cancer in African American Men

Video

CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Edmund Qiao, a fourth-year medical student from University of California San Diego and lead author of a study about prostate cancer prevention in African American men.

Given that African American men are more likely to be diagnosed with lethal prostate cancer at a younger age compared to non-Hispanic White men, the study aimed to determine interventional measures that may combat health disparities in this population. The study encompassed over 4000 men with a median age of 51.8 years and showed that increased intensity of prostate-specific antigen screening led to earlier detection and potential improvement in outcomes for younger African American men. 

Transcript:

This study emphasizes the importance of primary prevention of prostate cancer. We focus on the prostate-specific antigen screening for the basis of the presentation. One fact of our models is that we do include [primary care provider (PCP)]–utilization rates as well, [which is] basically a measure of how frequently a patient goes to the PCP. We did find that those were also significantly associated with a reduced risk of all of our end points. Taking [that] into context with the PSA screening, we feel that primary prevention of prostate cancer comes through primary care visits and just continuity of care. In terms of where [to] start, the primary prevention of prostate cancer is a very important aspect of the overall care.

References

Qiao E, Kotha N, Nalawade V, et al. Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes. J Clin Oncol. 2021;39(suppl 15):5004. doi: 10.1200/JCO.2021.39.15_suppl.5004

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Related Content